Attempting to Avoid Chemotherapy in CLL with Lenalidomide and Rituximab
Journal of Clinical Oncology (JCO) Podcast · Journals Online Team
May 27, 20148m 59s
Audio is streamed directly from the publisher (dts.podtrac.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
The current study, reporting on the upfront use of lenalidomide and rituximab in CLL, suggests high response rates and excellent tolerability in younger as well as older patients, albeit with a modest median progression-free survival.